Ctx and Impurities
| Brand | Product data | Purity | Price range | Estimated delivery |
|---|---|---|---|---|
 | CTX1 REF: 4Z-C-353001CAS: 501935-96-2 | - - - | To inquire | Tue 28 May 24 |
| CTX1-d6 REF: 4Z-C-353002CAS: 501935-96-2 | - - - | To inquire | Tue 28 May 24 |
 | BMS-813160 REF: TM-T4584CAS: 1286279-29-5 | 99.78% | 62.00 €~1,613.00 € | Tue 28 May 24 |
Ref: 4Z-C-353001
| 10mg | To inquire | |
| 25mg | To inquire | |
| 50mg | To inquire | |
| 100mg | To inquire |
Estimated delivery in United States, on Tuesday 28 May 2024
Ref: 4Z-C-353002
| 10mg | To inquire | |
| 25mg | To inquire | |
| 50mg | To inquire | |
| 100mg | To inquire |
Estimated delivery in United States, on Tuesday 28 May 2024
BMS-813160
CAS:1286279-29-5
BMS-813160 is the first dual CCR2/CCR5 antagonist to enter Clinical development for cardiovascular.
Formula:
C25H40N8O2
Purity:
99.78%
Color and Shape:
Solid
Molecular weight:
484.64
Ref: TM-T4584
| 1mg | 62.00 € | |
| 5mg | 134.00 € | |
| 10mg | 183.00 € | |
| 25mg | 334.00 € | |
| 50mg | 555.00 € | |
| 100mg | 792.00 € | |
| 500mg | 1,613.00 € | |
| 1ml*10 (DMSO) | 143.00 € |
Estimated delivery in United States, on Tuesday 28 May 2024
